Back to top

Analyst Blog

OncoGenex Pharmaceuticals, Inc. (OGXI - Snapshot Report) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study, Borealis-2, for the potential treatment of advanced or metastatic bladder cancer.

The investigator-sponsored, randomized, controlled phase II study will enroll 200 patients suffering from advanced or metastatic bladder cancer whose disease has progressed following initial platinum-based chemotherapy treatment.

This study will evaluate OGX-427 plus Sanofi’s (SNY - Analyst Report) Taxotere (docetaxel) in improving survival compared to Taxotere alone.

OGX-427 is also in another clinical trial, Borealis-1. A randomized, placebo-controlled phase II study, Borealis-1 is designed to evaluate the potential survival benefit, safety and tolerability of combining OGX-427 with gemcitabine and cisplatin in the first-line treatment of patients with advanced bladder cancer.

OncoGenex will decide on a phase III study of OGX-427 in bladder cancer if one of these two studies shows a survival advantage.

The most advanced candidate in OncoGenex’s pipeline is custirsen (phase III) under evaluation for the treatment of metastatic castrate-resistant prostate cancer in men and also for the treatment of patients with advanced, unresectable non-small cell lung cancer. OncoGenex has a global collaboration and license agreement with Teva Pharmaceutical Industries Ltd. (TEVA - Analyst Report) to develop and commercialize the candidate. Another candidate, OGX-225, for the solid tumors indication is in pre-clinical development.

OncoGenex and Teva currently carry a Zacks Rank #3 (Hold). Right now, Furiex Pharmaceuticals, Inc. looks more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.48 +6.16%
BITAUTO HOL… BITA 81.71 +5.12%
CHINA BIOLO… CBPO 48.00 +3.49%
CTPARTNERS… CTP 16.49 +3.19%
STRATTEC SE… STRT 73.90 +3.15%